side effects include:
headache
infection
chills
fever
nausea
myalgia
pain
flu syndrome
pain
acne
hematologic side effects
lymphocytosis
leukocytosis
thrombocytopenia
nervous system
side effects
headache
cases of guillain-barr syndrome
chronic inflammatory demyelinating polyneuropathy
facial palsy
transverse myelitis
patients
receiving efalizumab in the
postmarketing setting
case of efalizumab-induced aseptic meningitis
case of efalizumab-induced
efalizumab-induced isolated cerebral lupus-like syndrome
common nonspecific infection
upper respiratory infection
serious infections
requiring hospitalization
cellulitis
pneumonia
abscess
sepsis
bronchitis
gastroenteritis
aseptic meningitis
legionnaire
disease
vertebral osteomyelitis
patients
infection
)
immunologic side effects
infection
proportion of patients with serious infection
immune-mediated adverse reactions
hospitalization
inflammatory arthritis
rare cases of interstitial pneumonitis
transverse myelitis
bronchiolitis obliterans
aseptic meningitis
idiopathic hepatitis
sialadenitis
sensorineural hearing loss
postmarketing reports of serious infections
necrotizing fasciitis
tuberculosis pneumonia
bacterial sepsis with seeding of distant sites
severe pneumonia with neutropenia
worsening of infection
cellulitis
pneumonia
antimicrobial treatment
possible case of progressive multifocal leukoencephalopathy
pml
patients
case of immune-mediated pancytopenia
case of serum
sickness-like reaction
general
side effects
chills
pain
flu syndrome
fever
asthenia
gastrointestinal side effects
nausea
case of candida colitis
musculoskeletal side effects
myalgia
pain
arthralgia
serious adverse events of psoriasis
guttate subtypes
dermatologic side effects
acne
serious psoriasis
cases of papular psoriasis
case of hypertrichosis
case of repigmentation of vitiligo
malignancies
efalizumab-treated patients
non-melanoma skin cancer
non-cutaneous solid tumors
hodgkin
lymphoma
lymphoma
malignant melanoma
majority of the malignancies
non-melanoma skin cancers
basal cell
squamous cell
oncologic side effects
overall incidence of malignancies of any kind
patient-years for efalizumab
treated patients
patient-years for placebo-treated patients
hypersensitivity side effects
rate
placebo group
hepatic side effects
mean elevation in alkaline phosphatase
units/l
shift
normal values of alkaline phosphatase
efalizumab-treated patients
higher numbers of efalizumab-treated patients
elevations
more liver function tests
placebo-treated patients